Cat:GMP-h-FIB
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Fibrinogen disorders (congenital afibrinogenemia,
congenital hypofibrinogenemia, fibrinogen storage disease, congenital
dysfibrinogenemia, hereditary fibrinogen Aα-Chain amyloidosis, acquired
dysfibrinogenemia, congenital hypodysfibrinogenemia, and cryofibrinogenemia) and related syndrome. GeneMedi offers paired diagnostics grade Fibrinogen (FIB) antibodies (monoclonal antibody, mab) and antigens for Fibrinogen disorders (congenital afibrinogenemia,
congenital hypofibrinogenemia, fibrinogen storage disease, congenital
dysfibrinogenemia, hereditary fibrinogen Aα-Chain amyloidosis, acquired
dysfibrinogenemia, congenital hypodysfibrinogenemia, and cryofibrinogenemia) rapid test kit of Fibrinogen (FIB) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Fibrinogen disorders (congenital afibrinogenemia,
congenital hypofibrinogenemia, fibrinogen storage disease, congenital
dysfibrinogenemia, hereditary fibrinogen Aα-Chain amyloidosis, acquired
dysfibrinogenemia, congenital hypodysfibrinogenemia, and cryofibrinogenemia ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Fibrinogen (factor I) is a glycoprotein
complex, produced in the liver, that circulates in the blood of all
vertebrates. During tissue and vascular injury, it is converted enzymatically
by thrombin to fibrin and then to a fibrin-based blood clot. It helps create
blood clots, heal wounds, and grow new blood vessels in response to injury,
infection, or inflammation. Fibrinogen disorders are a set of hereditary or
acquired abnormalities in the quantity and/or quality of circulating
fibrinogens. These disorders include, congenital afibrinogenemia, congenital
hypofibrinogenemia, fibrinogen storage disease, congenital dysfibrinogenemia,
hereditary fibrinogen Aα-Chain amyloidosis, acquired dysfibrinogenemia,
congenital hypodysfibrinogenemia, and cryofibrinogenemia.
Product Description
Cat No. of Pruducts
GMP-h-FIB-Ag01:Recombinant Human FIB Protein
Product Name
Recombinant Human FIB Protein
Target
Fibrinogen
Alias of Target/Biomarker
FIB, FLRN, Nop1, RNU3IP1
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
Fibrinogen (FIB) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in FIB level test of Fibrinogen disorders (congenital afibrinogenemia,
congenital hypofibrinogenemia, fibrinogen storage disease, congenital
dysfibrinogenemia, hereditary fibrinogen Aα-Chain amyloidosis, acquired
dysfibrinogenemia, congenital hypodysfibrinogenemia, and cryofibrinogenemia) and related syndrome evaluation
Tag
His
Products description
Recombinant Human FIB Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-FIB-Ab01,GMP-h-FIB-Ab02:Anti-Human FIB mouse monoclonal antibody (mAb)
Product Name
Anti-Human FIB mouse monoclonal antibody (mAb)
Target
Alias of Target/Biomarker
FIB, FLRN, Nop1, RNU3IP1
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human Fibrinogen (FIB) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Fibrinogen (FIB) antibodies in FIB level test of Fibrinogen disorders (congenital afibrinogenemia,
congenital hypofibrinogenemia, fibrinogen storage disease, congenital
dysfibrinogenemia, hereditary fibrinogen Aα-Chain amyloidosis, acquired
dysfibrinogenemia, congenital hypodysfibrinogenemia, and cryofibrinogenemia) and related syndrome evaluation.
Tag
mFc
Products description
Anti-Human FIB mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Fibrinogen (FIB) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
